WallStreetZenWallStreetZen

NASDAQ: FLGT
Fulgent Genetics Inc Stock

$20.78-0.29 (-1.38%)
Updated Apr 12, 2024
FLGT Price
$20.78
Fair Value Price
$22.75
Market Cap
$618.93M
52 Week Low
$20.62
52 Week High
$44.09
P/E
-3.69x
P/B
0.54x
P/S
2.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$289.21M
Earnings
-$167.83M
Gross Margin
36.1%
Operating Margin
-57.63%
Profit Margin
-58%
Debt to Equity
0.09
Operating Cash Flow
$27M
Beta
1.27
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A

FLGT Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FLGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

FLGT ($20.78) is undervalued by 8.65% relative to our estimate of its Fair Value price of $22.75 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FLGT ($20.78) is not significantly undervalued (8.65%) relative to our estimate of its Fair Value price of $22.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FLGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FLGT due diligence checks available for Premium users.

Be the first to know about important FLGT news, forecast changes, insider trades & much more!

FLGT News

Valuation

FLGT fair value

Fair Value of FLGT stock based on Discounted Cash Flow (DCF)
Price
$20.78
Fair Value
$22.75
Undervalued by
8.65%
FLGT ($20.78) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FLGT ($20.78) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FLGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

FLGT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.69x
Industry
37.11x
Market
42.64x

FLGT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
4.17x
FLGT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

FLGT's financial health

Profit margin

Revenue
$70.5M
Net Income
-$128.1M
Profit Margin
-181.8%
FLGT's Earnings (EBIT) of -$166.67M... subscribe to Premium to read more.
Interest Coverage Financials
FLGT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$102.0M
Debt to equity
0.09
FLGT's short-term assets ($507.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FLGT's short-term assets ($507.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FLGT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FLGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$14.9M
Investing
$24.3M
Financing
-$26.0M
FLGT's operating cash flow ($27.00M)... subscribe to Premium to read more.
Debt Coverage Financials

FLGT vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
FLGT$618.93M-1.38%-3.69x0.54x
CSTL$550.65M-3.46%-9.37x1.41x
CDNA$441.67M-6.67%-2.41x1.69x
LAB$809.43M-4.12%-2.97x-5.47x
OPK$857.30M-4.28%-4.92x0.62x

Fulgent Genetics Stock FAQ

What is Fulgent Genetics's quote symbol?

(NASDAQ: FLGT) Fulgent Genetics trades on the NASDAQ under the ticker symbol FLGT. Fulgent Genetics stock quotes can also be displayed as NASDAQ: FLGT.

If you're new to stock investing, here's how to buy Fulgent Genetics stock.

What is the 52 week high and low for Fulgent Genetics (NASDAQ: FLGT)?

(NASDAQ: FLGT) Fulgent Genetics's 52-week high was $44.09, and its 52-week low was $20.62. It is currently -52.87% from its 52-week high and 0.78% from its 52-week low.

How much is Fulgent Genetics stock worth today?

(NASDAQ: FLGT) Fulgent Genetics currently has 29,784,771 outstanding shares. With Fulgent Genetics stock trading at $20.78 per share, the total value of Fulgent Genetics stock (market capitalization) is $618.93M.

Fulgent Genetics stock was originally listed at a price of $9.18 in Sep 29, 2016. If you had invested in Fulgent Genetics stock at $9.18, your return over the last 7 years would have been 126.36%, for an annualized return of 12.38% (not including any dividends or dividend reinvestments).

How much is Fulgent Genetics's stock price per share?

(NASDAQ: FLGT) Fulgent Genetics stock price per share is $20.78 today (as of Apr 12, 2024).

What is Fulgent Genetics's Market Cap?

(NASDAQ: FLGT) Fulgent Genetics's market cap is $618.93M, as of Apr 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Fulgent Genetics's market cap is calculated by multiplying FLGT's current stock price of $20.78 by FLGT's total outstanding shares of 29,784,771.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.